Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background: Increased clusterin levels have been reported in brain, cerebrospinal fluid (CSF), and plasma of Alzheimer’s disease (AD) patients. Because changes are also observed in mild cognitive impairment (MCI), a possible relationship between clusterin levels and early neurodegenerative changes in AD was suggested. Objectives: To determine whether clusterin concentrations could 1) serve as a diagnostic marker for AD, 2) predict disease progression in MCI, and 3) correlate with AD-biomarkers. Methods: Clusterin levels in CSF and plasma, as well as AD biomarker levels of A β 42 , Tau, and pTau in CSF and Mini-Mental State Examination scores (MMSE) were determined in 67 controls, 50 MCI, and 107 AD patients. Repeated MMSE was obtained for 44 MCI and 72 AD patients after, on average, 2.7 years. Results: Elevated clusterin concentrations in plasma, but not in CSF, were a risk factor for AD (HR 18.6; 95% CI 2.8–122), and related to cognitive decline in MCI ( r =−0.38; p < 0.01). An inverse relation between plasma clusterin levels and cognitive decline was observed in AD patients ( r = 0.23; p ≤0.05). In CSF, but not in plasma, clusterin levels correlated with Tau and pTau in all groups. Conclusion: Elevated plasma clusterin levels in MCI confer an increased risk for progression to AD, and more rapid cognitive decline. We speculate that clusterin levels in CSF may reflect its involvement in the earliest neurodegenerative processes associated with AD pathology. Whereas neither clusterin levels in CSF nor in plasma had diagnostic value, plasma clusterin levels may serve as a prognostic marker for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Thambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., Wahlund, L.-O., Westman, E., Kinsey, A., Güntert, A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.78 · Cited by 405
May, P. C., Lampert-Etchells, M., Johnson, S. A., Poirier, J., Masters, J. N., & Finch, C. E. (1990) · Neuron · doi:10.1016/0896-6273(90)90342-d · Cited by 339 · cited 2×
“Clusterin is involved in early stages of AD pathology [2, 11], and associates with diffuse plaques in non-demented cases [6].”
BackgroundGhiso, J., Matsubara, E., Koudinov, A., Choi-Miura, N. H., Tomita, M., Wisniewski, T., & Frangione, B. (1993) · Biochemical Journal · doi:10.1042/bj2930027 · Cited by 304
Plasma clusterin and the risk of Alzheimer disease
Schrijvers, E. M. C. (2011) · JAMA · doi:10.1001/jama.2011.381 · Cited by 220
Song, F., Poljak, A., Crawford, J., Kochan, N. A., Wen, W., Cameron, B., Lux, O., Brodaty, H., Mather, K., Smythe, G. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034078 · Cited by 214 · cited 2×
“2), which is in line with results of earlier studies in which plasma clusterin levels were found to be predictive of cognitive performance in elderly individuals with MCI [27] and AD [25].”
MethodResultDistribution of clusterin in Alzheimer brain tissue
McGeer, P. L., Kawamata, T., & Walker, D. G. (1992) · Brain Research · doi:10.1016/0006-8993(92)90071-g · Cited by 212 · cited 1×
“The notion of clusterin being a key player in AD pathology is substantiated by results from immunopathological studies, in which clusterin was found co-localized with dystrophic neurites as well as amyloid- (A ) in the amyloid plaques in AD brain [5–7].”
ResultNilselid, A.-M., Davidsson, P., Nägga, K., Andreasen, N., Fredman, P., & Blennow, K. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.12.005 · Cited by 104 · cited 1×
“Some reported elevated clusterin levels in the CSF of advanced AD patients [12, 13], while others observed a decrease [14].”
Background
Cited by
Human CNS barrier-forming organoids with cerebrospinal fluid production
Pellegrini, L., Bonfio, C., Chadwick, J., Begum, F., Skehel, M., & Lancaster, M. A. (2020) · Science · doi:10.1126/science.aaz5626 · Cited by 461
The good, the bad, and the opportunities of the complement system in neurodegenerative disease
Schartz, N. D., & Tenner, A. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02024-8 · Cited by 286
Cholesterol and Alzheimer’s Disease; From Risk Genes to Pathological Effects
Feringa, F. M., & van der Kant, R. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.690372 · Cited by 226
Complement in the pathogenesis of Alzheimer’s disease
Morgan, B. P. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0662-9 · Cited by 194
High-density lipoprotein-related cholesterol metabolism in Alzheimer's disease
Pedrini, S., Chatterjee, P., Hone, E., & Martins, R. N. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15170 · Cited by 22
Metadata
- Authors
- Jongbloed, W., van Dijk, K. D., Mulder, S. D., van de Berg, W. D. J., Blankenstein, M. A., van der Flier, W., & Veerhuis, R.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2015-06-26
- Volume
- 46
- Issue
- 4
- Pages
- 1103-1110
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2207268297
- Cited by
- 73
- References
- 12
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.